|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ABII 8-K filed Nov 8, 2007. UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The unaudited pro forma combined financial statements reported below consist of unaudited pro forma combined statements of operations for the six months ended June 30, 2007 and for the year ended December 31, 2006 and an unaudited pro forma combined balance sheet as of June 30, 2007. The unaudited pro forma combined financial statements reported below should be read in conjunction with our “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our audited combined financial statements and the notes thereto, and the unaudited interim combined financial statements and the notes thereto, all of which are included elsewhere in this information statement. The pro forma balance sheet adjustments assume that our separation and distribution from Abraxis BioScience occurred as of June 30, 2007. The pro forma adjustments to the combined statements of operations for the six months ended June 30, 2007 and for the year ended December 31, 2006 assume that the separation and distribution and the 2006 Merger occurred as of January 1, 2006. In connection with the separation and distribution, we will obtain the assets and liabilities constituting the proprietary products business that was previously being conducted primarily through Abraxis BioScience’s Abraxis Oncology and Abraxis Research components. Based on the pro forma combined balance sheet as of June 30, 2007, these assets and liabilities included assets of approximately $1.5 billion and liabilities of approximately $300 million. The following unaudited pro forma combined financial statements reflect Abraxis BioScience’s transfer to us of all of its interest in New Abraxis, LLC, the repayment in full of Old Abraxis’ revolving credit facility and the contribution to us of approximately $715 million in cash; the distribution by Abraxis BioScience to its stockholders of approximately 40 million shares of our common stock (which is based on the number of shares of Old Abraxis common stock outstanding at June 30, 2007, excluding shares held in treasury, and the distribution ratio of one share of our common stock for every four shares of Abraxis BioScience common stock outstanding); and the conversion of invested equity into stockholders’ equity. The unaudited pro forma combined balance sheet and statements of operations included in this information statement have been derived from our audited combined financial statements and our unaudited interim combined financial statements included elsewhere in this information statement and do not purport to represent what our financial position and results of operations actually would have been had the separation and distribution and the 2006 Merger occurred on the dates indicated, or to project our financial performance for any future period.
46
Table of Contents |
| |||||||
